Aytu BioScience (OTCQX: AYTU) is a commercial-stage specialty pharmaceutical company focused on novel products in the field of urology. Aytu’s current product portfolio consists of Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with low testosterone; ProstaScint®, the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging; and Primsol®, the only FDA-approved trimethoprim-only oral solution for urinary tract infections. The company is developing MiOXSYS®, a semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. For more information, visit the company’s website at www.aytubio.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net
